Actuate Therapeutics, Inc. Common stockACTU
About: Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Employees: 10
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,728% more capital invested
Capital invested by funds: $2.85M [Q3] → $80.5M (+$77.7M) [Q4]
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
90% more funds holding
Funds holding: 10 [Q3] → 19 (+9) [Q4]
49.84% more ownership
Funds ownership: 1.96% [Q3] → 51.8% (+49.84%) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 17% 1-year accuracy 33 / 197 met price target | 190%upside $20 | Buy Initiated | 17 Mar 2025 |
Financial journalist opinion









